Within the canSERV project EU-OPENSCREEN will focus on providing world-class services in the area of chemistry and drug discovery. The canSERV project, will make a wealth of services accessible through one central online platform from basic science up to clinical translation to create personalised medicine for cancer patients. The platform should be up and running in a couple of months. Open calls to the worldwide cancer community for the provision of funded services will be announced over the central online platform and will be advertised widely across the cancer community.
canSERV will connect, coordinate, and align existing oncology and complementary Research Infrastructures (RIs) alongside providing services in a synergistic, transnational way. This will capitalise on the critical mass of experts and cutting-edge services offered by canSERV RIs and their extended networks.
canSERV key points
- The EU-funded canSERV consortium will make innovative services available to cancer researchers, therefore supporting the goals of the EU Cancer Mission.
- Funded services can be requested through canSERV’s single, unified transnational accessplatform, which will be built to integrate unique cancer research services from all consortium partners.
- The consortium is committed to sustaining long-term, continuously offered access to current and future oncology services for Europe and beyond.
canSERV key objectives
- To offer at least 200 different unique Personalized Oncology (PO) relevant and valuable cutting-edge services for life science research in Europe over the next three years.
- To establish a single, unified, transnational access platform to request services and training.
- To ensure oncology-related data provided will be fully compliant with the FAIR principles, and complement and synergise with other relevant EU initiatives (e.g., EOSC, UNCAN.eu).
- To sustain the network and unified resources of oncology-related service provision beyond the duration of the project.
Overall, canSERV will accelerate the process of translating theoretical knowledge into personalised oncology clinical practice, that will give cancer patients faster and easier access to solutions and products.
The full press release can be found here.